Robert Nelsen

Robert Nelsen

Vermogen: 2 M $ op 31-05-2026

62 jaar
Health Technology
Commercial Services
Finance

Profiel

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), June Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx (EQRX), National Resilience, Prime Medicine, Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others.
He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association.
Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S.
from the University of Puget Sound with majors in Economics and Biology.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
31-03-2025 60.615 ( 0,06% ) 2 M $ 31-05-2026
05-06-2026 100.142 ( 0,06% ) 355 504 $ 31-05-2026
31-12-2024 150.000 ( 0,01% ) 50 336 $ 31-05-2026
04-06-2026 13.853 ( 0,01% ) 45 715 $ 31-05-2026

Actieve functies van Robert Nelsen

BedrijvenFunctieBegin
HUA MEDICINE (SHANGHAI) LTD. Voorzitter 23-04-2010
PRIME MEDICINE, INC. Directeur/Bestuurslid 01-09-2020
SANA BIOTECHNOLOGY, INC. Oprichter 13-07-2018
Oprichter 28-06-2010
Directeur/Bestuurslid 01-01-2022
Voorzitter -
Hua Medicine Technology (Hong Kong) Ltd.
Directeur/Bestuurslid 01-08-2010
Directeur/Bestuurslid -
Directeur/Bestuurslid -
░░░░ ░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░ ░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░

Eerdere bekende functies van Robert Nelsen

BedrijvenFunctieEinde
░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░░░░
Ervaring van Robert Nelsen in detail bekijken

Opleiding van Robert Nelsen

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

63

Eerstegraads connecties

80

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit80

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Process Industries

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Energy Minerals

Health Technology

Health Technology

Health Technology

Producer Manufacturing

Health Technology

Miscellaneous

Consumer Services

Technology Services

Consumer Services

Finance

Health Technology

Commercial Services

Health Technology

Commercial Services

Commercial Services

Commercial Services

Finance

Commercial Services

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Technology Services

Health Technology

Hua Medicine Technology (Hong Kong) Ltd.

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Health Services

Health Technology

Health Technology

Finance

Commercial Services

Brii Biosciences (Beijing) Co. Ltd.

Brii Biosciences (Hong Kong) Co. Ltd.

Health Technology

Finance

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

  1. Beurs
  2. Insiders
  3. Robert Nelsen
-40 %: de beste tools exclusief voor abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU